Form 4: Ginkgo Bioworks Director Shyam Sankar Reports Equity Compensation and Holdings Update

Ginkgo Bioworks Holdings, Inc. Director Shyam Sankar reported the vesting of restricted stock units and the grant of new stock options, increasing his beneficial ownership in the company.

Summary

• Director Shyam Sankar acquired 10,822 shares of Class A Common Stock on June 11, 2025, through the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Mr. Sankar beneficially owns 72,372 shares of Class A Common Stock.
• The RSUs, granted on June 13, 2024, vested in full on June 11, 2025, in accordance with the Issuer's Non-Employee Director Compensation Program, subject to his continued service.
• Mr. Sankar was granted 34,375 new stock options on June 12, 2025, with an exercise price of $9.29 per share.
• These new stock options will vest in substantially equal installments on each of the first three anniversaries of the grant date, becoming fully vested on the third anniversary, contingent on his continued service as a Non-Employee Director.
• The grant of new stock options is under the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 12, 2025.

Sentiment

Score: 6

Explanation: The filing details routine equity compensation for a non-employee director, including the vesting of previously granted RSUs and the grant of new stock options. This is a standard event that aligns the director's interests with shareholders, indicating continued commitment, which is mildly positive.

Positives

• The vesting of RSUs and grant of new stock options align the director's interests with those of shareholders, as his compensation is tied to the company's equity performance.
• The continued equity grants to a director indicate ongoing commitment and involvement from key management personnel.

Future Outlook

The newly granted stock options will vest in three equal annual installments, with full vesting on the third anniversary of the June 12, 2025 grant date, subject to the director's continued service.

Industry Context

This filing reflects standard practice in the biotechnology and technology sectors where non-employee directors often receive a significant portion of their compensation in the form of equity, such as restricted stock units and stock options, to align their long-term interests with those of the company's shareholders.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options for non-employee director compensation is a common practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to attract and retain qualified board members.
• The vesting schedule for the new stock options (three equal annual installments) is a typical structure designed to encourage long-term commitment and performance from directors.
• While specific compensation amounts vary by company size, industry, and individual director responsibilities, the general structure observed in this filing is consistent with compensation programs at comparable companies in the biotech and synthetic biology space.

Corporate Governance

Related Party Transactions

• Director Shyam Sankar received equity compensation (vested Restricted Stock Units and new stock options) from Ginkgo Bioworks Holdings, Inc. as part of his service as a Non-Employee Director. This is a standard compensation arrangement between a company and its director.

Stakeholder Impact

• Shareholders: The equity grants to a director can be viewed positively as they align the director's financial interests with the long-term performance of the company, potentially leading to more shareholder-friendly decisions.
• Employees: No direct impact mentioned, but a well-governed company with aligned leadership can indirectly benefit all employees.

Next Steps

• The newly granted stock options will vest in three equal annual installments on the first, second, and third anniversaries of June 12, 2025, subject to continued service.

Key Dates

Keywords

Ginkgo Bioworks Holdings Inc., DNA, Shyam Sankar, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Beneficial Ownership